Head-to-head · WeighScore
HumeCare+ vs NexLife
The verdict
NexLife takes it — 68.5/100 to 58.6/100.
NexLife grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NexLife is a LegitScript-certified telehealth platform offering compounded semaglutide (from $145/mo) and compounded tirzepatide (from $186/mo).
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | HumeCare+ | NexLife |
|---|---|---|
| WeighScore | 58.6/100 | 68.5/100 |
| Grade | C | C |
| Scorecard rank | #366 | #149 |
| Semaglutide | $199/mo (starting dose, compounded) | $165/mo (compounded) |
| Tirzepatide | Not disclosed | $215/mo (compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #366 · C
Strengths
- Pairs compounded semaglutide with continuous body-composition tracking (lose fat, preserve muscle)
- Includes a Hume Pod body-composition device at no extra cost
- From $199/mo, billed monthly, cancel anytime
- Backed by Hume Health, an established body-composition scale brand
- Clinician-prescribed and monitored with weekly tracking
Where it loses points
- Final medication pricing is gated behind an intake quiz
- Only semaglutide is shown on the marketing site (tirzepatide not confirmed)
- Prescribing medical group and pharmacy partner not named
- States of operation not published
- Not LegitScript-certified (no certification displayed)
Graded #149 · C
Strengths
- LegitScript certified platform
- Works exclusively with LegitScript-certified, NABP-accredited pharmacies — strongest pharmacy trust signal in the dataset
- Both semaglutide and tirzepatide at competitive pricing
- Semaglutide from $145/mo on the 12-month plan ($165/mo month-to-month) - among the lowest in the dataset
Where it loses points
- State availability not publicly disclosed
- Compounded only — no brand-name options
- Also covers hormone optimization and longevity
- Lowest advertised rates ($145 sema / $186 tirz) require a 12-month plan commitment
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.